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Resume 
Background. Lymphoma after heart transplantation (HT) has been associated with induction therapy and 
herpesvirus infection. It is not known whether anti-viral agents administered immediately after HT can reduce 
the incidence of lymphoma. 
Methods. This study was a retrospective review of 3,393 patients who underwent HT in Spain between 1984 
and December 2003. Variables examined included development of lymphoma and, as possible risk factors, 
recipient gender and age, induction therapies (anti-thymocyte globulin, OKT3 and anti–interleukin-2 receptor 
antibodies) and anti-viral prophylaxis (acyclovir or ganciclovir). To study the effect of evolving treatment 
strategy, three HT eras were considered: 1984 to 1995; 1996 to 2000; and 2001 to 2003. 
Results. Induction therapy was employed in >60% of HTs, and anti-viral prophylaxis in >50%. There were 62 
cases of lymphoma (3.1 per 1,000 person-years, 95% confidence interval: 2.4 to 4.0). Univariate analyses 
showed no influence of gender, age at transplant, HT era, pre-HT smoking or the immunosuppressive 
maintenance drugs used in the first 3 months post-HT. The induction agent anti-thymocyte globulin (ATG) 
was associated with increased risk of lymphoma, and prophylaxis with acyclovir with decreased risk of 
lymphoma. Multivariate analyses (controlling for age group, gender, pre-HT smoking and 
immunosuppression in the first 3 months with mycophenolate mofetil and/or tacrolimus) showed that 
induction increased the risk of lymphoma if anti-viral prophylaxis was not used (regardless of induction agent 
and anti-viral agent), but did not increase the risk if anti-viral prophylaxis was used. 
Conclusions. Induction therapies with ATG or OKT3 do or do not increase the risk of lymphoma depending 
on whether anti-viral prophylaxis with acyclovir or ganciclovir is or is not employed, respectively.
Post-transplant lymphoproliferative disorders (PTLDs) have been associated with Epstein–Barr 
virus (EBV) infection
1,2
 and with induction therapy.
3
 In the case of heart transplant (HT) patients, 
induction with OKT3 has been associated with PTLD in some studies,
4
 but not in others. 
5-7
 
Induction is currently used in 40% to 50% of HTs,
8
 mainly with anti-thymocyte globulin (ATG) or 
antibodies against interleukin-2 receptor (IL-2R) rather than OKT3.  
 
Anti-viral prophylaxis with acyclovir or ganciclovir was originally introduced mainly to 
combat cytomegalovirus. It presumably may also combat EBV and other viruses that may prove to 
be associated with PTLD, but whether it actually does has not been established. Thus, it is not 
known whether the efficacy of any such action is influenced by the use of induction therapy or 
itself influences any risk associated with induction therapy.  
 
The Spanish Post–Heart Transplant Tumour Registry (SPHTTR) is singular in that its 18 
collaborating centers— all the Spanish hospitals performing HTs—continually provide direct 
updates with data on tumors in all patients who have undergone HT in Spain since the initiation of 
heart transplantation in this country in 1984. In this investigation we report the incidence of post-
HT lymphoma among adult HT patients in Spain as well as the influence of immunosuppressive 
regimen, induction treatment and anti-viral prophylaxis. A fuller analysis that considers all 
neoplasias (not only lymphoma) will be published in due course.  
METHODS  
Patients  
A total of 4,089 patients aged >15 years who underwent heart transplantation in Spain between 
1984 and December 31, 2003 were identified in the SPHTTR. From these, we excluded the 695 
patients who died in the first 3 months after HT, and 1 patient for whom the date of diagnosis of a 
first post-HT tumor had not been recorded. The remaining 3,393 patients were followed up to 
December 2004. Some 84.7% of these patients were men, with a mean age at time of 
transplantation of 51.4 ± 11.0 years and a median follow-up time of 5.2 years (mean 5.8 ± 4.1 
years, maximum 20.2 years).  
Variables  
The outcome data analyzed included occurrence of post-HT lymphoma and date of diagnosis. 
The treatment variables considered were: use of induction therapy, and the agents employed for 
this purpose (OKT3, ATG, daclizumab, basiliximab); the agents used for maintenance 
immunosuppression (cyclosporine [CsA], tacrolimus, azathioprine, mycophenolate mofetil 
[MMF], everolimus, sirolimus); and the use of anti-viral prophylaxis, and the agents employed for 
this purpose (acyclovir in the first 3 months after HT, ganciclovir or either). Risk factors 
considered were pre-HT smoking (information on post-HT smoking was incomplete and therefore 
not evaluated) and age at HT (<45, 45 to 54, 55 to 64, ≥65 years). With a view toward evaluating 
the effect of changes in immunosuppressive practice or HT protocols, the era in which HT had 
been performed was also introduced as an independent variable; the three eras considered were 
1984 to 1997 (the pre-MMF era), 1998 to 2000 (the pre–IL-2R blocker MMF era) and 2001 to 
2003 (the IL-2R blocker era). Information on EBV status of donor and recipient was available for 
only 920 patients (27%), and was therefore excluded from the analyses.  
 
This research was approved by the institutional review board of each participating center.  
  
Statistical Analysis  
For each patient, the number of years at risk was defined as the time between the date of HT 
and December 2004 or death, whichever occurred first. The incidence of lymphoma per 1,000 
person-years was estimated for each gender and age group, and for follow-up to 3 and 6 months 
and 1, 2, 3, 4, 5 and 10 years. Univariate risk analyses were performed to estimate the influence of 
age group, gender, pre-HT smoking, HT era, MMF in the first 3 months, tacrolimus, induction 
therapy, induction with OKT3, induction with ATG, induction with basiliximab, induction with 
daclizumab, prophylaxis with acyclovir, prophylaxis with ganciclovir, and prophylaxis with either 
acyclovir or ganciclovir. Multivariate Poisson models were fitted in which the association of 
lymphoma with induction in general and with induction by OKT3 and by ATG was evaluated, 
while adjusting for age group, gender, pre-HT smoking and immunosuppression in the first 3 
months with MMF and/or tacrolimus, in each of four groups defined on the basis of anti-viral 
prophylaxis: patients given acyclovir; patients not given acyclovir; patients given acyclovir or 
ganciclovir; and patients given neither acyclovir nor ganciclovir. The criterion for statistical 
significance was p < 0.05.  
RESULTS  
Of the 3,393 patients included in this study, 1,801 (53.1%) underwent HT in the pre-MMF era 
(1984 to 1997), 844 (24.9%) in the intermediate era (1998 to 2000) and 748 (22%) in the anti–IL-
2R antibodies era (2001 to 2003). Some 48.9% of patients had been smokers before HT.  
 
Data on the use of individual immunosuppressive agents are listed in Table 1. Steroids were 
used by all patients in the first 3 months post-HT, and by 62.2% after 2 years. The use of CsA and 
azathioprine declined gradually with increasing time post-HT, whereas tacrolimus, MMF and 
sirolimus exhibited the reverse trend. OKT3, ATG, basiliximab and daclizumab were used almost 
exclusively in the first 3 months post-HT, presumably for induction therapy. On this basis, 
induction therapy was used in 60.5% of the patients. The duration of induction therapy was 7.8 ± 
3.9 days with OKT3, and 4.9 ± 3.3 days with ATG.  
 
Acyclovir was administered to 1,369 patients (40.3%) during the first 3 months post-HT, 
ganciclovir to 1,017 (30%) during the first month, and either acyclovir or ganciclovir (or both) to 
1,815 (53.5%). A total of 62 lymphomas developed in 62 patients. The overall incidence of 
lymphomas per 1,000 person-years was 3.1 (95% confidence interval [CI]: 2.4 to 4); incidence per 
1,000 person-years was 4.6 at 1 year after HT (95% CI: 2.8 to 7.6), 2.7 after 5 years (95% CI: 2 to 
3.8) and 3 after 10 years (95% CI: 2.3 to 3.9) (Table 2). The overall incidence was 3.1 per 1,000 
person-years for both men and women (p = 0.948), and did not vary significantly among the four 
age groups at HT.  
 
Univariate analyses (Table 3) showed no differences in incidence related to gender, age at 
transplant, HT era, pre-HT smoking, or immunosuppressive maintenance drugs used in the first 3 
months. ATG was associated with increased risk (relative risk [RR] = 2.4, 95% CI: 1.3 to 4.5; p = 
0.004), and anti-viral prophylaxis with acyclovir exhibited borderline association with decreased 
risk (RR = 0.6, 95% CI: 0.3 to 1.0; p = 0.05).  
 
Multivariate analyses were performed in which the association of lymphoma with OKT3, ATG 
or induction in general was estimated in each of the four anti-viral prophylaxis groups 
distinguished (i.e., patients given acyclovir, patients not given acyclovir, patients given acyclovir 
or ganciclovir, patients given neither acyclovir nor ganciclovir) while controlling for age group, 
gender, pre-HT smoking and immunosuppression in the first 3 months with MMF and/or 
tacrolimus. These analyses showed that increased risk of lymphoma was associated with both 
ATG and OKT3 among patients who were not given acyclovir (RR = 3.6 [95% CI 1.6 to 7.9] for 
ATG, 2.2 [95% CI: 1.4 to 7.0] for OKT3, 2.8 [95% CI: 1.5 to 5.4] for induction in general) and 
among patients given neither acyclovir nor ganciclovir (RR = 3.7 [95% CI: 1.6 to 8.3] for ATG, 
2.7 [95% CI: 1 to 7.4] for OKT3, 3.2 [95% CI: 1.6 to 6.6] for induction in general), but was not 
associated with either agent among patients given acyclovir or patients given either acyclovir or 
ganciclovir (Figure 1).  
Table 1. Demographics, Immunosuppressive Agents and Anti-viral 
Prophylaxis 
Clinical characteristics 
  
n 3,393 
Males (%)  84.7 
Age (mean ± SD)  51.4 ± 11 
Heart transplantation period (%)  
1984–1997  53.1 
1998–2000  24.9 
2000–2003  22 
Basal immunosuppression (%)  
Cyclosporine  79.1 
Azathioprine  60.5 
Tacrolimus  8.3 
MMF  25.6 
Sirolimus  0.4 
Everolimus  0.2 
OKT3  37.4 
ATG  14.3 
Basiliximab  5.6 
Daclizumab  3.4 
Anti-viral prophylaxis (%)  
Acyclovir (first 3 months)  40.3 
Ganciclovir (≥1 month)  30 
Acyclovir or ganciclovir  53.5 
  
 
ATG, anti-thymocyte globulin (also including thymoglobulin). 
 
Table 2. Incidence of Lymphomas 
 Lymphomas 
 Person-years Tumors IRa (95% CI)b 
    
Overall 19,885.1 62 3.1 (2.4–4) 
By follow-up    
3 months  847.3 3 3.5 (1.1–11) 
6 months  1,676.1 7 4.2 (2–8.8) 
1 year  3,262.6 15 4.6 (2.8–7.6) 
2 years  6,161.7 20 3.3 (2.1–5) 
3 years  8,679.8 22 2.5 (1.7–3.9) 
4 years  10,888.3 28 2.6 (1.8–3.7) 
5 years 12,789.0 35 2.7 (2–3.8) 
10 years  18,308.1 55 3 (2.3–3.9) 
    
 
a Incidence rate (IR) per 1,000 person-years. 
b CI, confidence interval. 
  
Table 3. Relative Risk (RR) of Lymphoma Associated With Various Factors 
(Univariate Analyses) 
 Lymphomas 
 RR (95% CI) p-value 
   
Gender   
Male  1 (0.5–2.1) 0.9483 
Female  1.00 — 
Age group   
<45  1.00 — 
45–54  0.7 (0.4–1.3) 0.2577 
55–64  0.8 (0.4–1.4) 0.3879 
≥65  1.1 (0.4–3.3) 0.8414 
Smoker pre-HT  1 (0.6–1.7) 0.9324 
HT period   
1984–1997  1.00 — 
1998–2000  0.9 (0.5–1.8) 0.8667 
2001–2003  0.7 (0.3–2) 0.5042 
MMF (yes/no)  0.8 (0.4–1.8) 0.6535 
Tacrolimus (yes/no)  0.8 (0.2–3.2) 0.7298 
Induction therapy  1.5 (0.9–2.5) 0.1497 
OKT3  1.2 (0.7–2.2) 0.5600 
ATG 2.4  (1.3–4.5) 0.0044 
Basiliximab  0.00 0.3163 
Daclizumab  0.00 0.4654 
Profilax   
Aciclovir  0.6 (0.3–1) 0.0500 
Ganciclovir  0.9 (0.5–1.6) 0.6795 
Aciclovir/ganciclovir  0.7 (0.4–1.2) 0.1921 
   
 
CI, confidence interval; HT, heart transplantation; MMF, mycophenolate mofetil; 
ATG, anti-thymocyte globulin (also including thymoglobulin). 
 
 
 
 
Figure 1. Effect of induction therapies on the risk of post-HT lymphomas for 
patients who were and were not given anti-viral prophylaxis with acyclovir, and 
for patients who were and were not given anti-viral prophylaxis with acyclovir or 
gancyclovir, after adjustment for gender, age group, pre-HT smoking and MMF 
or tacrolimus in the first 3 months. RR, relative risk; CI, confidence interval.  
 
  
DISCUSSION 
This study reviewed 3,393 HT patients, 61% of whom had received induction therapy and 54% 
anti-viral prophylaxis. Sixty-two patients developed lymphoma, representing an overall incidence 
of 3.1 per 1,000 person-years (95% CI: 2.4 to 4). Overall incidence was not affected by gender or 
age at HT.  
 
Among Spanish HT patients, the incidence of lymphoma per 1,000 person-years during 
successive 1-year periods has been greatest during the first year post-HT (as in Opelz et al’s 
analysis of the CTS database
9
), but then fell and eventually leveled off at about 3.8, as can be 
calculated from the data in Table 2.  
 
The incidence of lymphoma was not affected by immunosuppressive maintenance regimen or 
HT period. Univariate analysis indicates that the only induction agent increasing the risk of 
lymphoma was ATG (Table 3); risk was not increased by either OKT3 or IL-2R blockers. In a 
retrospective review of 154 HT patients, Swinnen et al
4
 observed the opposite trend: the incidence 
of PTLD was 9-fold higher among OKT3- treated patients than among others (most of whom had 
received ATG induction therapy). The difference between our results and those of Swinnen and 
colleagues is likely attributable to the use of different OKT3 doses: their OKT3 induction regimen 
was 5 mg/day for 14 days; the mean duration of OKT3 induction in the present study was 7.8 days 
(SD 3.9 days) and, in general, Spanish centers reduced the dose and/or duration of OKT3 
induction during the 1990s.
10,11
 A sharp post-1990 fall in the incidence of lymphoma among 
OKT3-induced patients in the CTS database has similarly been attributed to probable reductions in 
dose and treatment duration.
9
  
 
Although the utility of induction therapy after HT is still a matter of debate,
12-15
 it is used in 
many centers because it allows delayed institution of immunosuppression with calcineurin 
inhibitors, and therefore spares renal function. According to the latest ISHLT report,
8
 around 50% 
of patients now receive induction therapy, mainly with IL-2R blocking antibodies and polyclonal 
ATG; the use of OKT3 has been decreasing. Induction therapy, if it is a risk factor, is in principle 
an avoidable one. Induction agents did not emerge as a risk factor in one study of a subset of 
ISHLT cases evaluated by O’Neill and colleagues.16 The proportion of our patients given some 
kind of induction therapy, 61%, is about 1.3 times the ISHLT average for the period 1996 to 
2004,
8
 and about 1.5 times the proportion in O’Neill et al’s study16 (37%), but does not appear to 
have led to a greater incidence of lymphomas. It is necessary, however, to distinguish among 
different induction agents: in the present study, induction with IL-2R blockers did not increase the 
risk of PTLD, and we know of no reports of them doing so.  
 
Since the early 1990s, anti-viral agents have been administered in many centers to transplant 
patients prophylactically during the first 3 months to reduce the risk of herpesvirus disease, 
especially cytomegalovirus (CMV) disease. For CMV, prophylaxis appears to be successful.
17
 
Also, prophylaxis with ganciclovir has been reported to reduce the risk of PTLD in kidney 
transplant patients.
18
 In this study we found that prophylaxis with ganciclovir or acyclovir 
significantly reduced the risk of post-HT lymphoma. More specifically, multivariate analyses 
showed that, in the absence of anti-viral prophylaxis, induction with ATG and induction with 
OKT3 both increased the incidence of lymphomas, whereas risk was not increased by any 
induction treatment if anti-viral prophylaxis was employed (either acyclovir in the first 3 months 
after HT, or ganciclovir in the first month). How acyclovir and ganciclovir achieve this reduction 
in risk is unknown; the investigators in the kidney transplant study suggested that, because both 
acyclovir and ganciclovir act only during the lytic stage of infection, their efficacy for anti-viral 
prophylaxis must be due to action during the initial infection with EBV or during re-activation of a 
latent infection.
18
 To our knowledge, the present study is the first to assess the influence of anti-
viral prophylaxis on whether induction therapy increases the risk of post-HT lymphoma.  
 
The most obvious limitation of this study is the paucity of data on EBV serology in the 
SPHTTR (these data are available for only 27% of patients), which prevented investigation of 
whether the efficacy of anti-viral prophylaxis in reducing the risk of PTLD depends on EBV 
status.   
In conclusion, among Spanish HT patients, induction therapy other than with IL-2R 
antagonists has in general significantly increased the risk of lymphomas, except when acyclovir or 
ganciclovir were administered prophylactically after HT. If induction with OKT3 or antithymocyte 
globulin is utilized, anti-viral prophylaxis should also be employed to reduce the risk of post-HT 
lymphoma.  
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APPENDIX  
The following investigators also participated in the Spanish Post–Heart Transplant Tumour Registry: Maria J. 
Paniagua and Jose A Rodriguez (Complejo Hospitalario Universitario Juan Canalejo, La Coruña); Javier 
Segovia and Manuel Gomez- Bueno (Clinica Puerta de Hierro, Madrid); Carmen Segura Saint-Gerons 
(Hospital Universitario Reina Sofia, Córdoba); Luis Martinez-Doltz (Hospital Universitario La Fe, Valencia); 
Miguel Angel Gómez-Sanchez and Pilar Escribano (Hospital Universitario 12 de Octubre, Madrid); Juan 
Fernández-Yáñez (Hospital General Universitario Gregorio Marañón, Madrid); Josep Roca (Hospital 
Universitario de Bellvitche, Barcelona); Matias Ubilla (Clínica Universitaria de Navarra, Pamplona); Maria 
Martin-Fernández and Jose L. Rodriguez-Lambert (Hospital Universitario Central de Asturias, Oviedo); Félix 
Perez- Villa (Hospital Clinic i Provincial, Barcelona); Iris P. Garrido (Hospital Universitario Virgen de la 
Arrixaca, Murcia); Maria Luisa Sanz-Julve (Hospital Universitario Miguel Server, Zaragoza); Javier López-
Diaz (Hospital Clinico Universitario, Valladolid); Vicens Brossa and Sonia Mirabet (Hospital de la Santa 
Creu i San Pau, Barcelona); and Francisco Gonzalez-Vichez (Hospital Universitario Marqués de Valdecilla, 
Santander).  
 
 
